Q1 EPS Estimates for TG Therapeutics Lifted by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX) – HC Wainwright raised their Q1 2026 EPS estimates for shares of TG Therapeutics in a note issued to investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings per share of $0.24 for the quarter, up from their previous forecast of $0.23. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q2 2026 earnings at $0.28 EPS, Q3 2026 earnings at $0.34 EPS and FY2030 earnings at $4.01 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, March 2nd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.21). The business had revenue of $192.57 million during the quarter, compared to analyst estimates of $192.15 million. TG Therapeutics had a net margin of 72.56% and a return on equity of 119.68%. The company’s revenue was up 78.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.15 earnings per share.

Several other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. JPMorgan Chase & Co. lowered their price target on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Finally, Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $50.00.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $30.09 on Friday. The stock has a market cap of $4.78 billion, a price-to-earnings ratio of 10.86 and a beta of 1.85. TG Therapeutics has a twelve month low of $25.28 and a twelve month high of $46.48. The company’s fifty day moving average is $29.85 and its 200 day moving average is $31.42. The company has a quick ratio of 2.89, a current ratio of 3.82 and a debt-to-equity ratio of 0.40.

Institutional Trading of TG Therapeutics

Several large investors have recently modified their holdings of TGTX. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at $25,000. Danske Bank A S bought a new stake in TG Therapeutics in the third quarter valued at $25,000. Optiver Holding B.V. raised its holdings in shares of TG Therapeutics by 3,485.7% during the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 732 shares during the period. Bessemer Group Inc. boosted its position in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new position in shares of TG Therapeutics during the 3rd quarter worth about $34,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics News Summary

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Record BRIUMVI-driven revenue growth — Q4 total revenue rose ~78% y/y with U.S. BRIUMVI net revenue of $182.7M and full‑year 2025 BRIUMVI sales of ~$594M (≈+90% y/y); management raised BRIUMVI revenue guidance for 2026, underpinning top‑line momentum. TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
• Positive Sentiment: Analyst model upgrades — HC Wainwright raised Q1–Q3 2026 and FY2030 EPS estimates, signaling growing sell‑side confidence in profitability as BRIUMVI scales. Upgrades can support the stock over the coming quarters. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Meaningful pipeline & commercialization catalysts — Investors highlight potential upside from the Phase 3 ENHANCE study (consolidated dosing) and development of a self‑administered subcutaneous BRIUMVI formulation, which could expand addressable market and margins if successful. TG Therapeutics: ‘Strong Buy’ On BRIUMVI’s Massive Growth
• Neutral Sentiment: Company reaffirmed 2026 revenue outlook and held a conference call outlining commercial execution and retention metrics — positive context, but near‑term stock reaction depends on reconciling EPS miss with guidance. TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Big EPS disappointment — Reported EPS of $0.14 vs. consensus ~$0.35 (≈-60% surprise); the profit miss is the main short‑term catalyst for the share decline despite strong revenues. TGTX Q4 Earnings Lag Estimates (Zacks)
• Negative Sentiment: Near-term volatility risk — Large EPS miss increases odds of short‑term selling pressure and gives traders a reason to pare back positions until subsequent quarters show margin improvement or clearer evidence that guidance will be achieved. TG Therapeutics (TGTX) Misses Q4 Earnings Estimates

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.